colorectal disease
Conditions
Interventions
Niflec 2000ml with Gasmotin 15mg
Niflec 2000ml with placebo
Niflec 1500ml with Gasmotin 15mg
Sponsors
Aichi Cancer Center Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Out patients who underwent colonoscopy in our hospital 2.patients provided a written informed consent
Exclusion criteria
Exclusion criteria: 1.patients with chronic and acute renal failure (Cr>1.5mg/dl) 2.patients with uncontroled congenital heart failure and unstable angina 3.patients with acute myocardial infarction (AMI) and recieved A-C bypass or intervention for AMI within 3 months 4.abnormal serum sodium, pottassium, phosphorus, and calcium 5.active phase patients with inflammatory bowel disease 6.history of colonic surgery 7.sign of bowel obstruction 8.sign of bowel perforation 9.patients with toxic megacolon 10.patients with suffering from diverticulotitis 11.severe constipatien 12.history of drug allergy 13.sign of pregnancy 14.patients with advanced colorectal cancer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| tolerability of bowel preparation with polyethylene glycol electrolyte lavage | — |
Secondary
| Measure | Time frame |
|---|---|
| quality of bowel preparation, consumption time to take lavage, time to first defecation, time to completion of bowel cleansing, additional volume of lavage to completion of bowel cleansing, occurrence of unpleasant abdominal symptom, and posibility of reduction in requred volume of volume of lavage | — |
Countries
Japan
Outcome results
None listed